Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Non-Current Debt: 2016-2024

Historic Non-Current Debt for Viridian Therapeutics, Inc.\DE (VRDN) over the last 6 years, with Dec 2024 value amounting to $20.6 million.

  • Viridian Therapeutics, Inc.\DE's Non-Current Debt rose 1.79% to $20.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 1.79%. This contributed to the annual value of $20.6 million for FY2024, which is 1.87% up from last year.
  • Viridian Therapeutics, Inc.\DE's Non-Current Debt amounted to $20.6 million in FY2024, which was up 1.87% from $20.2 million recorded in FY2023.
  • Over the past 5 years, Viridian Therapeutics, Inc.\DE's Non-Current Debt peaked at $20.6 million during FY2024, and registered a low of $20.2 million during FY2023.
  • Moreover, its 2-year median value for Non-Current Debt was $20.4 million (2023), whereas its average is $20.4 million.
  • Data for Viridian Therapeutics, Inc.\DE's Non-Current Debt shows a peak YoY rose of 1.87% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Viridian Therapeutics, Inc.\DE's Non-Current Debt stood at $20.2 million in 2023, then rose by 1.87% to $20.6 million in 2024.